12 wyniki
FIELD OF THE INVENTION
The present invention relates to a method of treating patients who have breast cancer.
More particularly, the invention relates to treatment of patients with a taxol solution administered as a 96 hour continuous infusion every 21 days.
BACKGROUND OF THE INVENTION
Taxol is a
BACKGROUND OF THE INVENTION
Taxol is a member of the taxane family of diterpenes, having the structure shown below: ##STR2##
The numbering system shown for taxol is that recommended by IUPAC (IUPAC, Commission on the Nomenclature of Organic Chemistry, 1978).
The chemistry of the potent anticancer
BACKGROUND OF THE INVENTION
Cancer is one of the leading causes of death in our country today. Despite extensive research, a cure for cancer is not yet a reality. Taxol is known to be cytotoxic against numerous malignant tumors. The results of studies indicate that taxol has been effective against
BACKGROUND OF THE INVENTION
The present invention relates to 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamide derivatives, and to pharmaceutical compositions and methods of treatment of inflammation, cancer and other disorders.
The compounds of the present invention are inhibitors
FIELD OF THE INVENTION
The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the
FIELD OF THE INVENTION
The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the
FIELD OF THE INVENTION
The present invention relates to pharmaceutical preparations (i.e., composition) for use as tumor suppressive agents for tumors arising from cancers such as prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial and ovarian cancers, and benign prostate
FIELD OF THE INVENTION
The present invention relates to pharmaceutical preparations (i.e., composition) for use as tumor suppressive agents for tumors arising from cancers such as prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial and ovarian cancers, and benign prostate
FIELD OF THE INVENTION
The present invention relates to pharmaceutical preparations (i.e., composition) for use as tumor suppressive agents for tumors arising from cancers such as prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial and ovarian cancers, and benign prostate
DESCRIPTION
1. Field of the Invention
The present invention is in the field of elemene analogs and elemenal analogues. In particular, the present invention relates to processes for the preparation of (-)-beta-elemene, (-)-beta-elemenal (a (-)-beta-elemene metabolite in mammals), (-)-beta-elemenol,
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the field of cancer treatment. More specifically, the present invention relates to the unexpected synergistic effects of nuclear transcription factor NF-.kappa.B inhibitors and anti-neoplastic agents in
RELATED APPLICATIONS
This application is the U.S. National Phase of International Application No. PCT/GB2007/001720, filed 10 May 2007, published in English, which application claims priority under 35 U.S.C. .sctn.119 or 365 to Great Britain Application No. 0609386.8, filed 11 May 2006. The entire